The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review

被引：23
作者：
Braat M.N.G.J.A. [1 ]
Samim M. [2 ]
van den Bosch M.A.A.J. [1 ]
Lam M.G.E.H. [1 ]
机构：
[1] Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, Utrecht
[2] Department of Surgery, University Medical Center Utrecht, Utrecht
来源：
Clinical and Translational Imaging | 2016年 / 4卷 / 4期
关键词：
Bridge to transplant; Downstaging; Future liver remnant; Radioembolization;
D O I：
10.1007/s40336-016-0172-0
中图分类号：
学科分类号：
摘要：
Radioembolization (RE) is an emerging treatment strategy for patients with primary hepatic malignancies and metastatic liver disease. Though RE is primarily performed in the palliative setting, a shift toward the curative setting is seen. Currently, hepatic resection and in selected cases liver transplantation are the only curative options for patients with a hepatic malignancy. Unfortunately, at diagnosis most patients are not eligible for liver surgery due to the imbalance between the necessary liver resection and the remaining liver remnant. However, in borderline resectable cases, tumor volume reduction and/or increasing the future liver remnant can lead to a resectable situation. The combination of selective tumor treatment, the induction of hypertrophy of untreated liver segments, and its favourable toxicity profile make RE an appealing strategy for downstaging. The present review discusses the possibilities for RE in the preoperative setting as a downstaging tool or as a bridge to liver transplantation. © 2016, The Author(s).
引用
收藏
页码：283 / 295
页数：12
相关论文
共 108 条
  • [81] Lam M.G., Louie J.D., Iagaru A.H., Goris M.L., Sze D.Y., Safety of repeated yttrium-90 radioembolization, Cardiovasc Intervent Radiol, 36, 5, pp. 1320-1328, (2013)
  • [82] de Graaf W., van Lienden K., Dinant S., Et al., Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection, J Gastrointest Surg., 14, 2, pp. 369-378, (2010)
  • [83] Denys A.P.J., Bize P., Et al., Portal vein embolization: what do we know?, Cardiovasc Intervent Radiol, 35, 5, pp. 999-1008, (2012)
  • [84] de Baere T.T.C., Deschamps F., Et al., Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization, Ann Surg Oncol, 17, 8, pp. 2081-2089, (2010)
  • [85] Farges O.B.J., Kianmanesh R., Et al., Portal vein embolization before right hepatectomy: prospective clinical trial, Ann Surg Oncol, 237, 2, pp. 208-217, (2003)
  • [86] Simoneau E., Aljiffry M., Salman A., Abualhassan N., Cabrera T., Valenti D., Et al., Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases, HPB (Oxford)., 14, 7, pp. 461-468, (2012)
  • [87] Correa D.S.L., Jarnagin W.R., Et al., Kinetics of liver volume changes in the first year after portal vein embolization, Arch Surg, 145, 4, pp. 351-354, (2010)
  • [88] Kokudo N., Tada K., Seki M., Ohta H., Azekura K., Ueno M., Et al., Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization, Hepatology, 34, 2, pp. 267-272, (2001)
  • [89] Al-Sharif E., Simoneau E., Hassanain M., Portal vein embolization effect on colorectal cancer liver metastasis progression: lessons learned, World J Clin Oncol., 6, 5, pp. 142-146, (2015)
  • [90] de Graaf W., Bennink R.J., Vetelainen R., van Gulik T.M., Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation, J Nucl Med, 51, 5, pp. 742-752, (2010)
234567891011